New FDA Rules Clarify Generic Drug Equivalence Tests
Published Date: 5/29/2026
Notice
Summary
The FDA just released final guidance to help drug companies prove their generic drugs work just like the original ones by using bioequivalence studies. This affects anyone submitting or updating abbreviated new drug applications (ANDAs) and aims to make the approval process clearer and smoother. Companies should review these new rules now to avoid delays and extra costs when getting their generics to market.
Analyzed Economic Effects
5 provisions identified: 5 benefits, 0 costs, 0 mixed.
Final BE Guidance for ANDA Applicants
The FDA issued final guidance titled "Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA" on May 29, 2026. The guidance gives recommendations to applicants planning to include bioequivalence (BE) information in abbreviated new drug applications (ANDAs), ANDA amendments, and ANDA supplements and is intended to make the approval process clearer and smoother so companies should review it now to avoid delays and extra costs when getting generics to market.
Key Updates from Draft to Final
The final guidance includes updates to align recommendations with the M13A guidance issued October 31, 2024, clarifications about study population and study design, updates to in vitro dissolution testing information, and removal of certain statistical-analysis appendices (those appendices were incorporated into the concurrently issued guidance "Statistical Approaches to Establishing Bioequivalence").
Which Products the Guidance Covers
The guidance applies to immediate-release and modified-release oral dosage forms and to non-oral drug products where systemic exposure measures can establish bioequivalence, for example transdermal delivery systems and certain rectal and nasal drug products. It also applies when applicants plan BE studies during the postapproval period for changes to a drug product approved under an ANDA.
Guidance Is Non-Binding; Alternatives Allowed
The guidance represents FDA's current thinking but does not establish any rights and is not binding on FDA or the public; applicants may use an alternative approach if it satisfies applicable statutes and regulations. FDA finalized this guidance consistent with its good guidance practices (21 CFR 10.115).
No New Information Collection Burden
The guidance itself contains no new collection of information. It refers to previously approved information collections under several OMB control numbers (for example, OMB control numbers 0910-0130, 0910-0572, 0910-0014, 0910-0291, 0910-0001, 0910-0191, 0910-0727, and 0910-0119) that remain subject to the Paperwork Reduction Act of 1995 review.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-10702 — State of Indiana: NRC Staff Assessment of a Proposed Agreement Between the Nuclear Regulatory Commission and the State of Indiana
The Nuclear Regulatory Commission (NRC) is teaming up with Indiana to let the state take charge of some nuclear safety rules. This means Indiana will handle certain nuclear materials oversight, helping protect public health while keeping things running smoothly. People have until June 15, 2026, to share their thoughts before the agreement moves forward—no big costs or delays expected!
Next: 2026-10704 — Extension of Lebanon Designation for Temporary Protected Status
Lebanon’s Temporary Protected Status (TPS) has been extended for six more months, from May 28 to November 27, 2026. This means Lebanese TPS holders can keep living and working in the U.S. without worry while the government reviews conditions back home. The extension happened automatically because recent events in Lebanon delayed the usual review process.